NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 385,600 shares, a decrease of 18.1% from the August 31st total of 470,700 shares. Based on an average daily volume of 392,400 shares, the days-to-cover ratio is presently 1.0 days. Currently, 2.7% of the shares of the stock are sold short.

NeuroSense Therapeutics Stock Performance

NRSN traded up $0.01 during midday trading on Monday, hitting $1.28. The stock had a trading volume of 64,400 shares, compared to its average volume of 278,903. The company has a market cap of $17.49 million, a P/E ratio of -1.51 and a beta of 1.52. NeuroSense Therapeutics has a 1 year low of $0.40 and a 1 year high of $2.33. The business has a fifty day moving average of $0.93 and a 200 day moving average of $1.15.

Institutional Investors Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. XTX Topco Ltd acquired a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned 0.24% of NeuroSense Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 1.04% of the stock is currently owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.